Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient will benefit from treatment with therapeutic agents that inhibit Hepatitis C virus (HCV). These methods are based on detecting HCV RNA and/or anti-HCV antibodies in small-volume dried biological fluid samples that are collected using a microsampling device. Kits for use in practicing the methods are also provided.

Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient will benefit from treatment with therapeutic agents that inhibit Hepatitis C virus (HCV). These methods are based on detecting HCV RNA and/or anti-HCV antibodies in small-volume dried biological fluid samples that are collected using a microsampling device. Kits for use in practicing the methods are also provided.

Abstract: The invention concerns perfumed, free flowing concentrated laundry detergent powders (concentrates), having a ratio of total solid constituents to total liquid constituents of less than 30:1, wherein the perfume is sorbed onto carrier particles which release at least 60% w/w/ of the perfume in the Perfume Release Test and which are inert as defined by the Perfume Stability Test. The invention also concerns perfume-on-carrier systems designed for perfuming free flowing concentrated laundry detergent powders. Preferably the carrier particles are inorganic and have a perfume content of at least 25% w/w.